P1308PHOSPHATE-LOWERING USING SUCROFERRIC OXYHYDROXIDE: CALCIFICATION PROPENSITY (T50) IN HEMODIALYSIS PATIENTS. POST-HOC ANALYSES OF A RANDOMIZED, CONTROLLED CLINICAL TRIAL. (6th June 2020)
- Record Type:
- Journal Article
- Title:
- P1308PHOSPHATE-LOWERING USING SUCROFERRIC OXYHYDROXIDE: CALCIFICATION PROPENSITY (T50) IN HEMODIALYSIS PATIENTS. POST-HOC ANALYSES OF A RANDOMIZED, CONTROLLED CLINICAL TRIAL. (6th June 2020)
- Main Title:
- P1308PHOSPHATE-LOWERING USING SUCROFERRIC OXYHYDROXIDE: CALCIFICATION PROPENSITY (T50) IN HEMODIALYSIS PATIENTS. POST-HOC ANALYSES OF A RANDOMIZED, CONTROLLED CLINICAL TRIAL
- Authors:
- Thiem, Ursula
Marculescu, Rodrig
Pasch, Andreas
Haller, Maria
Cejka, Daniel - Abstract:
- Abstract: Background and Aims: Lowering serum phosphate with sucroferric oxyhydroxide (SO) therapy reduces calcification propensity (measured with the T50 test) in hemodialysis patients (Cejka et al. Abstract FR-PO149, ASN Kidney Week 2019). Intriguingly, we observed considerable inter-patient variability for changes in T50 in response to SO treatment, despite similar reductions in serum phosphate. Method: Post-hoc analysis of a randomized, controlled cross-over study investigating the effects of serum phosphate lowering using oral phosphate binder therapy with SO on calcification propensity (T50 ). Patients with changes of serum phosphate of approximately -0.5 mmol/l between phosphate binder wash-out and high dose (2000 mg/d) SO and were selected and classified as "responders" (showing profound changes in T50 ) and "non-responders" (showing very little change in T50 ). Data are shown as means ± SD. Results: "Responders" (N=4) and "non-responders" (N=4) showed similar degrees of lowering of serum phosphate with high-dose SO treatment (-0.47 ± 0.06 vs. -0.49 ± 0.01 mmol/l). "Responders" showed marked increases in T50 (+108 ± 26 min), but "non-responders" did not (+6 ± 24 min). When comparing other laboratory parameters during the wash-out phase between "responders" and "non-responders", no obvious difference in single parameters or pattern of laboratory parameters was apparent for ionized calcium (1.11 ± 0.1 vs. 1.01 ± 0.1 mmol/l), phosphate (1.76 ± 0.31 vs. 2.06 ± 0.47Abstract: Background and Aims: Lowering serum phosphate with sucroferric oxyhydroxide (SO) therapy reduces calcification propensity (measured with the T50 test) in hemodialysis patients (Cejka et al. Abstract FR-PO149, ASN Kidney Week 2019). Intriguingly, we observed considerable inter-patient variability for changes in T50 in response to SO treatment, despite similar reductions in serum phosphate. Method: Post-hoc analysis of a randomized, controlled cross-over study investigating the effects of serum phosphate lowering using oral phosphate binder therapy with SO on calcification propensity (T50 ). Patients with changes of serum phosphate of approximately -0.5 mmol/l between phosphate binder wash-out and high dose (2000 mg/d) SO and were selected and classified as "responders" (showing profound changes in T50 ) and "non-responders" (showing very little change in T50 ). Data are shown as means ± SD. Results: "Responders" (N=4) and "non-responders" (N=4) showed similar degrees of lowering of serum phosphate with high-dose SO treatment (-0.47 ± 0.06 vs. -0.49 ± 0.01 mmol/l). "Responders" showed marked increases in T50 (+108 ± 26 min), but "non-responders" did not (+6 ± 24 min). When comparing other laboratory parameters during the wash-out phase between "responders" and "non-responders", no obvious difference in single parameters or pattern of laboratory parameters was apparent for ionized calcium (1.11 ± 0.1 vs. 1.01 ± 0.1 mmol/l), phosphate (1.76 ± 0.31 vs. 2.06 ± 0.47 mmol/l), T50 (285 ± 82 vs 271 ± 38 min), albumin (3.9 ± 0.2 vs. 4.1 ± 0.4 g/dl), magnesium (1.07 ± 0.17 vs. 0.98 ± 0.14 mmol/l), bicarbonate (22.0 ± 3.6 vs. 24.1 ± 3.0 mmol/l), iPTH (301 ± 156 vs. 463 ± 303 pg/dl) or iFGF23 (6903 ± 9480 vs. 1097 ± 927 pg/ml). Conclusion: Similar degrees of phosphate lowering do not lead to a similar improvements in T50. T50 "responders" versus "non-responders" cannot be identified using current standard laboratory parameters. … (more)
- Is Part Of:
- Nephrology dialysis transplantation. Volume 35(2020)Supplement 3
- Journal:
- Nephrology dialysis transplantation
- Issue:
- Volume 35(2020)Supplement 3
- Issue Display:
- Volume 35, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 35
- Issue:
- 3
- Issue Sort Value:
- 2020-0035-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-06-06
- Subjects:
- Nephrology -- Periodicals
Hemodialysis -- Periodicals
Kidneys -- Transplantation -- Periodicals
Hemodialysis
Kidneys -- Transplantation
Nephrology
Periodicals
616.61 - Journal URLs:
- http://ndt.oxfordjournals.org/ ↗
http://www.oup.co.uk/ndt/ ↗
http://ukcatalogue.oup.com/ ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0931-0509;screen=info;ECOIP ↗ - DOI:
- 10.1093/ndt/gfaa142.P1308 ↗
- Languages:
- English
- ISSNs:
- 0931-0509
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6075.685300
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15209.xml